Norwegian urology-focused developer Photocure ASA said last week it won a supplemental new drug application from the FDA extending the indication for its Blue Light Cytoscopy (BLC) with Cysview to include flexible cytoscopes designed for the surveillance of patients with bladder cancer.
The company touted the approval, saying it is the only combination of drugs and devices approved for detecting bladder cancer.
Read the whole story on our sister site, Drug Delivery Business
The post Photocure wins FDA expanded sNDA for Blue Light Cytoscopy with Cysview system appeared first on MassDevice.
from MassDevice http://ift.tt/2EEEo9u
Cap comentari:
Publica un comentari a l'entrada